Radiolabelled Peptides for Oncological Diagnosis

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2012 Mar 6

PMID 22388627

Citations 33

Authors

Peter Laverman

Jane K Sosabowski

Otto C Boerman

Wim J G Oyen

Affiliations

Soon will be listed here.

Abstract

Radiolabelled receptor-binding peptides targeting receptors (over)expressed on tumour cells are widely under investigation for tumour diagnosis and therapy. The concept of using radiolabelled receptor-binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. The (111)In-labelled somatostatin analogue octreotide (OctreoScan) is the most successful radiopeptide for tumour imaging, and was the first to be approved for diagnostic use. Based on the success of these studies, other receptor-targeting peptides such as cholecystokinin/gastrin analogues, glucagon-like peptide-1, bombesin (BN), chemokine receptor CXCR4 targeting peptides, and RGD peptides are currently under development or undergoing clinical trials. In this review, we discuss some of these peptides and their analogues, with regard to their potential for radionuclide imaging of tumours.

Citing Articles

A Novel Luciferase-Based Reporter Gene Technology for Simultaneous Optical and Radionuclide Imaging of Cells.

Gaspar N, Handula M, Stroet M, Marella-Panth K, Haeck J, Kirkland T Int J Mol Sci. 2024; 25(15).

PMID: 39125775 PMC: 11312113. DOI: 10.3390/ijms25158206.

Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.

Migliari S, Sammartano A, Boss M, Gotthardt M, Scarlattei M, Baldari G Molecules. 2022; 27(2).

PMID: 35056858 PMC: 8778103. DOI: 10.3390/molecules27020543.

[Ga]Ga-DFO-c(RGDyK): Synthesis and Evaluation of Its Potential for Tumor Imaging in Mice.

Krajcovicova S, Daniskova A, Bendova K, Novy Z, Soural M, Petrik M Int J Mol Sci. 2021; 22(14).

PMID: 34299008 PMC: 8306578. DOI: 10.3390/ijms22147391.

The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems.

Lu L, Chen H, Hao D, Zhang X, Wang F Asian J Pharm Sci. 2020; 14(6):595-608.

PMID: 32104486 PMC: 7032227. DOI: 10.1016/j.ajps.2019.04.004.

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Velikyan I, Eriksson O Theranostics. 2020; 10(1):437-461.

PMID: 31903131 PMC: 6929622. DOI: 10.7150/thno.38366.

References

Scopinaro F, De Vincentis G, Varvarigou A, Laurenti C, Iori F, Remediani S . 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003; 30(10):1378-82. DOI: 10.1007/s00259-003-1261-7. View

Aloj L, Aurilio M, Rinaldi V, dAmbrosio L, Tesauro D, Peitl P . Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011; 38(8):1417-25. DOI: 10.1007/s00259-011-1816-y. View

La Bella R, Garcia-Garayoa E, Langer M, Blauenstein P, Beck-Sickinger A, Schubiger P . In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol. 2002; 29(5):553-60. DOI: 10.1016/s0969-8051(02)00314-1. View

Innis R, Snyder S . Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980; 77(11):6917-21. PMC: 350402. DOI: 10.1073/pnas.77.11.6917. View

de Visser M, Bernard H, Erion J, Schmidt M, Srinivasan A, Waser B . Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging. 2007; 34(8):1228-38. DOI: 10.1007/s00259-006-0356-3. View

Brans L, Maes V, Garcia-Garayoa E, Schweinsberg C, Daepp S, Blauenstein P . Glycation methods for bombesin analogs containing the (NalphaHis)Ac chelator for 99mTc(CO)3 radiolabeling. Chem Biol Drug Des. 2008; 72(6):496-506. DOI: 10.1111/j.1747-0285.2008.00727.x. View

von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather S . Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem. 2009; 52(15):4786-93. DOI: 10.1021/jm900400w. View

Jacobson O, Weiss I, Szajek L, Farber J, Kiesewetter D . 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem. 2009; 17(4):1486-93. PMC: 2723765. DOI: 10.1016/j.bmc.2009.01.014. View

Reubi J, Korner M, Waser B, Mazzucchelli L, Guillou L . High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004; 31(6):803-10. DOI: 10.1007/s00259-004-1476-2. View

10.

Karra S, Schibli R, Gali H, Katti K, Hoffman T, Higginbotham C . 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjug Chem. 1999; 10(2):254-60. DOI: 10.1021/bc980096a. View

11.

Liu Z, Niu G, Wang F, Chen X . (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009; 36(9):1483-94. DOI: 10.1007/s00259-009-1123-z. View

12.

Lin K, Luu A, Baidoo K, Hashemzadeh-Gargari H, Chen M, Brenneman K . A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem. 2005; 16(1):43-50. DOI: 10.1021/bc049820h. View

13.

Roosenburg S, Laverman P, Joosten L, Eek A, Oyen W, de Jong M . Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem. 2010; 21(4):663-70. DOI: 10.1021/bc900465y. View

14.

Nock B, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt J . CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med. 2005; 46(10):1727-36. View

15.

Laverman P, Joosten L, Eek A, Roosenburg S, Peitl P, Maina T . Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011; 38(8):1410-6. PMC: 3127012. DOI: 10.1007/s00259-011-1806-0. View

16.

Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage E . PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011; 8(5):1775-82. PMC: 3185201. DOI: 10.1021/mp200141x. View

17.

Baidoo K, Lin K, Zhan Y, Finley P, Scheffel U, Wagner Jr H . Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998; 9(2):218-25. DOI: 10.1021/bc9701959. View

18.

Schroeder R, van Weerden W, Bangma C, Krenning E, de Jong M . Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods. 2009; 48(2):200-4. DOI: 10.1016/j.ymeth.2009.04.002. View

19.

Dapp S, Garcia Garayoa E, Maes V, Brans L, Tourwe D, Muller C . PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Nucl Med Biol. 2011; 38(7):997-1009. DOI: 10.1016/j.nucmedbio.2011.02.014. View

20.

Liu Z, Yan Y, Liu S, Wang F, Chen X . (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2010; 20(5):1016-25. PMC: 2895820. DOI: 10.1021/bc9000245. View